A groundbreaking tetravalent FAP-DR5 antibody has been developed to efficiently initiate apoptosis in tumor cells in preclinical models, particularly targeting FAP-positive stromal environments (Brünker et al., 2016). Here, TNFRSF10B is linked to neoplasm.